NCT03888092View on ClinicalTrials.gov

Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

August 18, 2017

Primary Completion Date

December 13, 2022

Study Completion Date

December 13, 2022

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Z650

receive oral Z650 once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days

Trial Locations (1)

100071

Chinese PLA General Hospital, the Fifth Medical Center, Beijing

All Listed Sponsors
lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY

NCT03888092 - Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification | Biotech Hunter | Biotech Hunter